Statins for the prevention of contrast-induced nephropathy: A systematic review and meta-analysis

American Journal of Nephrology

Volumn 33, Issue 4, 2011, Pages 344-351

  Zhang, Tuo ^a   Shen, Ling Hong ^a   Hu, Liu Hua ^a   He, Ben ^a  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

Contrast induced nephropathy; Meta analysis; Statins; Systematic review

Indexed keywords

ACETYLCYSTEINE; ATORVASTATIN; CREATININE; IODIXANOL; IOHEXOL; IOPAMIDOL; PLACEBO; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN;

CHRONIC DRUG ADMINISTRATION; COHORT ANALYSIS; CONTRAST INDUCED NEPHROPATHY; CREATININE BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG MEGADOSE; HUMAN; LOW DRUG DOSE; META ANALYSIS; PRIORITY JOURNAL; PROSPECTIVE STUDY; QUALITATIVE RESEARCH; QUANTITATIVE ANALYSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RENAL PROTECTION; RETROSPECTIVE STUDY; REVIEW; SYSTEMATIC REVIEW;

AGED; COHORT STUDIES; CONTRAST MEDIA; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; KIDNEY DISEASES; MIDDLE AGED; PLACEBOS; REGRESSION ANALYSIS; RISK; RISK FACTORS; TREATMENT OUTCOME;

EID: 79952820559     PISSN: 02508095     EISSN: None     Source Type: Journal    
DOI: 10.1159/000326269     Document Type: Review

References (35)

1. McCullough PA: Contrast-induced acute kidney injury. J Am Coll Cardiol 2008; 51: 1419-1428.
2. Reed MC, Moscucci M, Smith DE, Share D, LaLonde T, Mahmood SA, D'Haem C, Mc- Namara R, Greenbaum A, Gurm HS: The relative renal safety of iodixanol and low-osmolar contrast media in patients undergoing percutaneous coronary intervention. Insights from Blue Cross Blue Shield of Michigan Cardiovascular Consortium (BMC2). J Invasive Cardiol 2010; 22: 467-472.
3. Laskey W, Aspelin P, Davidson C, Rudnick M, Aubry P, Kumar S, Gietzen F, Wiemer M: Nephrotoxicity of iodixanol versus iopamidol in patients with chronic kidney disease and diabetes mellitus undergoing coronary angiographic procedures. Am Heart J 2009; 158: 822-828.e3.
4. From AM, Al Badarin FJ, McDonald FS, Bartholmai BJ, Cha SS, Rihal CS: Iodixanol versus low-osmolar contrast media for prevention of contrast induced nephropathy: metaanalysis of randomized, controlled trials. Circ Cardiovasc Interv 2010; 3: 351-358.
5. Heinrich MC, Haberle L, Muller V, Bautz W, Uder M: Nephrotoxicity of iso-osmolar iodixanol compared with nonionic lowosmolar contrast media: meta-analysis of randomized controlled trials. Radiology 2009; 250: 68-86.
6. Reed M, Meier P, Tamhane UU, Welch KB, Moscucci M, Gurm HS: The relative renal safety of iodixanol compared with low-osmolar contrast media: a meta-analysis of randomized controlled trials. JACC Cardiovasc Interv 2009; 2: 645-654.
7. From AM, Bartholmai BJ, Williams AW, Cha SS, McDonald FS: Mortality associated with nephropathy after radiographic contrast exposure. Mayo Clin Proc 2008; 83: 1095-1100.
8. McCullough PA, Wolyn R, Rocher LL, Levin RN, O'Neill WW: Acute renal failure after coronary intervention: incidence, risk factors, and relationship to mortality. Am J Med 1997; 103: 368-375.
9. Rihal CS, Textor SC, Grill DE, Berger PB, Ting HH, Best PJ, Singh M, Bell MR, Barsness GW, Mathew V, Garratt KN, Holmes DR Jr: Incidence and prognostic importance of acute renal failure after percutaneous coronary intervention. Circulation 2002; 105: 2259-2264.
10. Eisenberg RL, Bank WO, Hedgock MW: Renal failure after major angiography can be avoided with hydration. AJR Am J Roentgenol 1981; 136: 859-861.
11. Aspelin P, Aubry P, Fransson SG, Strasser R, Willenbrock R, Berg KJ: Nephrotoxic effects in high-risk patients undergoing angiography. N Engl J Med 2003; 348: 491-499.
12. Barrett BJ, Carlisle EJ: Metaanalysis of the relative nephrotoxicity of high- and low-osmolality iodinated contrast media. Radiology 1993; 188: 171-178.
13. McCullough PA: Multimodality prevention of contrast-induced acute kidney injury. Am J Kidney Dis 2008; 51: 169-172.
14. Katholi RE, Woods WT Jr, Taylor GJ, Deitrick CL, Womack KA, Katholi CR, McCann WP: Oxygen free radicals and contrast nephropathy. Am J Kidney Dis 1998; 32: 64-71.
15. Russo D, Minutolo R, Cianciaruso B, Memoli B, Conte G, De Nicola L: Early effects of contrast media on renal hemodynamics and tubular function in chronic renal failure. J Am Soc Nephrol 1995; 6: 1451-1458.
16. Farmer JA: Pleiotropic effects of statins. Curr Atheroscler Rep 2000; 2: 208-217.
17. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gotzsche PC, Ioannidis JP, Clarke M, Devereaux PJ, Kleijnen J, Moher D: The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. J Clin Epidemiol 2009; 62:e1-e34.
18. Ivanova V, Spotti J, Vido DA, Lasorda DM, Biederman RW: Can contrast induced nephropathy be prevented via a renal pleotropism effect from statins? J Am Coll Cardiol 2009; 53:A38-A38.
19. Kandula P, Shah R, Singh N, Markwell SJ, Bhensdadia N, Navaneethan SD: Statins for prevention of contrast-induced nephropathy in patients undergoing non-emergent percutaneous coronary intervention. Nephrology (Carlton) 2010; 15: 165-170.
20. Khanal S, Attallah N, Smith DE, Kline-Rogers E, Share D, O'Donnell MJ, Moscucci M: Statin therapy reduces contrast-induced nephropathy: an analysis of contemporary percutaneous interventions. Am J Med 2005; 118: 843-849.
21. Yoshida S, Kamihata H, Nakamura S, Senoo T, Manabe K, Motohiro M, Sugiura T, Iwasaka T: Prevention of contrast-induced nephropathy by chronic pravastatin treatment in patients with cardiovascular disease and renal insufficiency. J Cardiol 2009; 54: 192-198.
22. Zhao JL, Yang YJ, Zhang Yh, You SJ, Wu YJ, Gao RL: Effect of statins on contrast-induced nephropathy in patients with acute myocardial infarction treated with primary angioplasty. Int J Cardiol 2008; 126: 435-436.
23. Patti G, Nusca A, Chello M, Pasceri V, D'Ambrosio A, Vetrovec GW, Di Sciascio G: Usefulness of statin pretreatment to prevent contrast-induced nephropathy and to improve long-term outcome in patients undergoing percutaneous coronary intervention. Am J Cardiol 2008; 101: 279-285.
24. Ozhan H, Erden I, Ordu S, Aydin M, Caglar O, Basar C, Yalcin S, Alemdar R: Efficacy of short-term high-dose atorvastatin for prevention of contrast-induced nephropathy in patients undergoing coronary angiography. Angiology 2010; 61: 711-714.
25. Toso A, Maioli M, Leoncini M, Gallopin M, Tedeschi D, Micheletti C, Manzone C, Amato M, Bellandi F: Usefulness of atorvastatin (80 mg) in prevention of contrast-induced nephropathy in patients with chronic renal disease. Am J Cardiol 2010; 105: 288-292.
26. Jo SH, Koo BK, Park JS, Kang HJ, Cho YS, Kim YJ, Youn TJ, Chung WY, Chae IH, Choi DJ, Sohn DW, Oh BH, Park YB, Choi YS, Kim HS: Prevention of radiocontrast medium-induced nephropathy using short-term highdose simvastatin in patients with renal insufficiency undergoing coronary angiography (PROMISS) trial - a randomized controlled study. Am Heart J 2008; 155: 499.e1-8.
27. Wang Z, Chen HL, Pan YD: Effect of atorvastatin on renal function in patients given contrast medium after interventional procedures. Med J Chinese People 8 Armed Police Forces 2009; 20: 919-922.
28. Xinwei J, Xianghua F, Jing Z, Xinshun G, Ling X, Weize F, Guozhen H, Yunfa J, Weili W, Shiqiang L: Comparison of usefulness of simvastatin 20 mg versus 80 mg in preventing contrast-induced nephropathy in patients with acute coronary syndrome undergoing percutaneous coronary intervention. Am J Cardiol 2009; 104: 519-524.
29. Zhou X, Jin YZ, Wang Q, Min R, Zhang XY: Efficacy of high dose atorvastatin on preventing contrast induced nephropathy in patients underwent coronary angiography (in Chinese). Zhonghua Xin Xue Guan Bing Za Zhi 2009; 37: 394-396.
30. Bellosta S, Ferri N, Bernini F, Paoletti R, Corsini A: Non-lipid-related effects of statins. Ann Med 2000; 32: 164-176.
31. Schonbeck U, Libby P: Inflammation, immunity, and HMG-CoA reductase inhibitors: statins as antiinflammatory agents? Circulation 2004; 109:II18-II26.
32. Mason RP, Walter MF, Jacob RF: Effects of HMG-CoA reductase inhibitors on endothelial function: role of microdomains and oxidative stress. Circulation 2004; 109:II34- II41.
33. Kelly AM, Dwamena B, Cronin P, Bernstein SJ, Carlos RC: Meta-analysis: effectiveness of drugs for preventing contrast-induced nephropathy. Ann Intern Med 2008; 148: 284-294.
34. Liu R, Nair D, Ix J, Moore DH, Bent S: Nacetylcysteine for the prevention of contrastinduced nephropathy. A systematic review and meta-analysis. J Gen Intern Med 2005; 20: 193-200.
35. Duong MH, MacKenzie TA, Malenka DJ: N-acetylcysteine prophylaxis significantly reduces the risk of radiocontrast-induced nephropathy: comprehensive meta-analysis. Catheter Cardiovasc Interv 2005; 64: 471-479.